非小细胞肺癌的驱动基因EGFR有个不是很常见的突变位点——20号外显子插入突变，这个突变类型占所有EGFR突变的6%左右，使用第一代和第二代EGFR靶向药治疗EGFR基因的20外显子插入突变，治疗应答率仅为10%左右，中位无进展生存时间大概为1到3个 ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

In this video, Xiuning Le, MD, PhD, discusses how the definition of EGFR-mutated lung cancer has expanded in recent years.

In this video, Xiuning Le, MD, PhD, discusses the greatest areas of unmet need in the treatment of EGFR-mutated lung cancer.

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...

The global cancer diagnostics market size was valued at USD 106.32 billion in 2024 and is projected to reach from USD 112.60 ...